GlassScriptPhysician profile
Edward Jinki Chang
NPI 1811953615
$5,893.23
in general payments reported to CMS, 2019-2025
21 companies · $465 in 2025
The $465 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,453 · 2020: $535 · 2021: $798 · 2022: $852 · 2023: $1,246 · 2024: $544 · 2025: $465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,254.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,372.50 | 2019-2025 | Argos, Clareon, Rocklatan |
| Allergan, INC. | $1,219.98 | 2019-2022 | |
| Abbvie INC. | $1,010.14 | 2022-2025 | Xen Glaucoma Treatment System, Lumigan, Alphagan P |
| Regeneron Healthcare Solutions, INC. | $423.02 | 2020-2025 | Eylea Hd, Eylea |
| New World Medical,INC. | $388.66 | 2019-2023 | |
| Aerie Pharmaceuticals, INC. | $287.50 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $222.37 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $221.45 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $187.29 | 2022-2025 | Vyzulta, Miebo, Lotemax Sm |
| Johnson & Johnson Surgical Vision, INC. | $115.67 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $110.65 | 2019-2021 | |
| Oyster Point Pharma, INC. | $94.64 | 2022-2025 | Tyrvaya, Ryzumvi |
| Glaukos Corporation | $50.25 | 2024-2025 | Istent Trabecular Micro-Bypass System Model Is3, Istent Infinite |
| Johnson & Johnson Vision Care, INC. | $32.85 | 2023-2024 | Acuvue |
| Astellas Pharma US INC | $28.50 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ivantis, INC | $26.84 | 2020 | |
| Genentech USA, INC. | $23.76 | 2024 | Vabysmo |
| Thea Pharma INC. | $23.55 | 2023 | Iyuzeh |
| Apellis Pharmaceuticals, INC. | $19.73 | 2025 | Syfovre |
| Akorn, INC. | $17.10 | 2020 | |
| Quidel Corporation | $16.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.